Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Keith Tapper is an analyst at BMO Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/26/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11/20/2024 | NGNE | Buy Now | Neurogene | $14.06 | 220.06% | Keith Tapper20% | $60 → $45 | Maintains | Outperform | Get Alert |
| 11/12/2024 | NGNE | Buy Now | Neurogene | $14.06 | 326.74% | Keith Tapper20% | $65 → $60 | Maintains | Outperform | Get Alert |
| 06/27/2024 | TSHA | Buy Now | Taysha Gene Therapies | $1.70 | 194.12% | Keith Tapper20% | → $5 | Initiates | → Outperform | Get Alert |
| 06/27/2024 | ACAD | Buy Now | ACADIA Pharmaceuticals | $17.11 | 81.18% | Keith Tapper20% | → $31 | Initiates | → Outperform | Get Alert |
| 06/27/2024 | NGNE | Buy Now | Neurogene | $14.06 | 362.3% | Keith Tapper20% | → $65 | Initiates | → Outperform | Get Alert |
